iifl-logo-icon 1

Glenmark Life Sciences Ltd Share Price

848.3
(0.73%)
Jul 12, 2024|03:32:41 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open838
  • Day's High866.9
  • 52 Wk High972
  • Prev. Close842.15
  • Day's Low837.5
  • 52 Wk Low581.1
  • Turnover (lac)10,389.07
  • P/E21.93
  • Face Value2
  • Book Value212.94
  • EPS38.43
  • Mkt. Cap (Cr.)10,393.98
  • Div. Yield2.67
No Records Found

Glenmark Life Sciences Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

838

Prev. Close

842.15

Turnover(Lac.)

10,389.07

Day's High

866.9

Day's Low

837.5

52 Week's High

972

52 Week's Low

581.1

Book Value

212.94

Face Value

2

Mkt Cap (₹ Cr.)

10,393.98

P/E

21.93

EPS

38.43

Divi. Yield

2.67

Glenmark Life Sciences Ltd Corporate Action

9 Oct 2023

12:00 AM

Dividend

Dividend Amount: 22.5

Record Date: 17 Oct, 2023

arrow

18 Apr 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

1 Sep 2023

12:00 AM

BookCloser

arrow

24 Aug 2023

12:00 AM

AGM

Announcement Date: 24 Aug, 2023

arrow

Glenmark Life Sciences Ltd NEWS AND UPDATE

Glenmark Pharmaceuticals divests stake in Glenmark Life after Nirma Acquisition
11 Jul 2024|01:16 PM

The sale will be conducted through the stock exchange mechanism, adhering to applicable legal requirements.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Glenmark Life Sciences Ltd SHAREHOLDING SNAPSHOT

15 Jul, 2024|07:19 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 82.84%

Foreign: 0.00%

Indian: 82.84%

Non-Promoter- 6.41%

Institutions: 6.41%

Non-Institutions: 10.73%

Custodian: 0.00%

Share Price

Glenmark Life Sciences Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

24.51

24.51

1.96

1.96

Preference Capital

0

0

0

0

Reserves

2,113.7

2,029.81

750.79

399.73

Net Worth

2,138.21

2,054.32

752.75

401.69

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021

Revenue

1,885.16

yoy growth (%)

Raw materials

-905.49

As % of sales

48.03

Employee costs

-149.13

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021

Profit before tax

470.94

Depreciation

-33.39

Tax paid

-119.36

Working capital

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021

Growth matrix (%)

Revenue growth

Op profit growth

EBIT growth

Net profit growth

View Ratios
Particulars (Rupees in Crores.)Mar-2021Mar-2020Mar-2019

Gross Sales

1,885.17

1,537.31

886.42

Excise Duty

0

0

0

Net Sales

1,885.17

1,537.31

886.42

Other Operating Income

0

0

0

Other Income

0.81

11.99

0.44

Glenmark Life Sciences Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,577.3

124.083,78,675.04867.60.865,536.9998.75

Cipla Ltd

CIPLA

1,512.05

32.871,22,092.681,038.40.563,444.92346.41

Divis Laboratories Ltd

DIVISLAB

4,539.3

76.441,20,480.265310.662,259507.93

Zydus Lifesciences Ltd

ZYDUSLIFE

1,175.15

34.281,18,217.41,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,719.45

26.171,12,137.091,034.80.595,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Glenmark Life Sciences Ltd

Management

Register Office

Registrar Office

Chairman & Non Executive Dir.

Glenn Saldanha

Non Executive Director

V S Mani

Managing Director & CEO

Yasir Yusufali Rawjee

E D & Wholetime Director

Vinod Naik

Independent Non Exe. Director

Sridhar Gorthi

Independent Non Exe. Director

Manju Agarwal

Independent Non Exe. Director

Taruvai Laxminarayanan Easwar

Independent Non Exe. Director

Gita Nayyar

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

The company was incorporated as Zorg Laboratories Private Limited, a private limited company under the Companies Act, 1956 on 23 June 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune (RoC). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited pursuant to a special resolution passed by the shareholders of the Company on 25 July 2018 and a fresh certificate of incorporation dated 10 August 2018 was issued by the RoC. A shareholders resolution was passed on 13 August 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January 2019.The company is primarily engaged in the business of development,manufacture and marketing of Active Pharmaceutical Ingredients(APIs). The companys R&D facilities are located at Mahape,Ankleshwar and Dahej and manufacturing facilities are located at Ankleshwar,Dahej,Mohol and Kurkumbh.During the year 2018-19, the company allotted 4,50,090 Equity Shares of Rs. 10/- each on the conversion of loan given to Director. During the year, 15,00,000
Read More

Company FAQs

What is the Glenmark Life Sciences Ltd share price today?

Down Arrow

The Glenmark Life Sciences Ltd shares price on N/A is Rs.₹849.25 today.

What is the Market Cap of Glenmark Life Sciences Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Life Sciences Ltd is ₹10405.62 Cr. as of 12 Jul ‘24

What is the PE and PB ratio of Glenmark Life Sciences Ltd?

Down Arrow

The PE and PB ratios of Glenmark Life Sciences Ltd is 21.93 and 4.43 as of 12 Jul ‘24

What is the 52 Week High and Low of Glenmark Life Sciences Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Glenmark Life Sciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Glenmark Life Sciences Ltd is ₹582.8 and ₹970 as of 12 Jul ‘24

What is the CAGR of Glenmark Life Sciences Ltd?

Down Arrow

Glenmark Life Sciences Ltd's CAGR for 5 Years at N/I%, 3 Years at 4.31%, 1 Year at 42.88%, 6 Month at 14.82%, 3 Month at 4.94% and 1 Month at -1.43%.

What is the shareholding pattern of Glenmark Life Sciences Ltd?

Down Arrow

The shareholding pattern of Glenmark Life Sciences Ltd is as follows:
Promoters - 82.85 %
Institutions - 6.42 %
Public - 10.73 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.